Evaluating Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index

NCT07161557 | Not Yet Recruiting

• 1 other identifier: 24-RD-10-AY-001
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to evaluate Metabolic Health by fit analysis between calculated Nutrilite Metabolic Health Index and the result of Metabolomics analysis from blood plasma samples in healthy adult participants aged between 18 and 60 years. The main question it aims to answer: \- Does the Nutrilite Metabolic Health Index fit well with the result of Metabolomics analysis from blood plasma samples? 200 eligible participants will be enrolled in a single center, one site visit will be made to finish a health questionnaire, a lifestyle questionnaire, a routine physical checkup. Blood samples will be collected for routine blood test (blood sugar, total triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid), and for Metabolomics testing. Researchers will calculate the Nutrilite Metabolic Health Index based on participant data, and do the fit analysis against the result from Metabolomics analysis.

Conditions

Metabolic Abnormality; Metabolic Disorders

Keywords

Diet2Me; Nutrilite Metabolic Health Index; Metabolic health omics model; Metabolomics testing

Outcome Measures

Primary Outcomes (1)

• Nutrilite Metabolic Health Index

  Nutrilite Metabolic Health Index incorporates seven core biochemical parameters (see details in Secondary Outcome Measures): body mass index (BMI), waist circumference, fasting blood glucose (FBG) level, blood lipid profile (total cholesterol (TC), total triglycerides(TG), Low-Density Lipoprotein Cholesterol (LDL), High-Density Lipoprotein Cholesterol (HDL), blood pressure (Systolic Blood Pressure(SBP), and Diastolic Blood Pressure (BDP)), uric acid level, and history of fatty liver disease; along with four lifestyle and hereditary factors: smoking, alcohol consumption, age, and family history of metabolic diseases. After weighted calculation, the index score ranges from 0 to 100, divided into four grades: Excellent: 85-100 Moderate: 60-84 Poor: 40-59 Severe: 0-39

  day 1

Secondary Outcomes (10)

• SBP

  day 1

• DBP

  day 1

• Blood test - LDL-C

  day 1

• Blood test - HDL-C

  day 1

• Blood test - TG

  day 1

Study Arms (1)

All participants

All participants enrolled will be asked to fill out the questionnaires, have physical checkup, and take blood samples, no interventions involved.

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational Cohort OTHER

No intervention involved, participants will fill out some questionnaires and blood samples will drawn for test and analysis.

All participants

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Male and female participants, aged 18 to 60, regardless of gender;

You may qualify if:

• Male and female volunteers, aged 18 to 60, regardless of gender;
• Not participating in other interventional clinical studies;
• Have a good understanding of the nature, purpose, benefits obtained, and possible risks and side effects of the study;
• Willing to comply with all trial requirements and procedures;
• Sign the informed consent form.

You may not qualify if:

• In the treatment of gastrointestinal symptoms;
• Those who are lactose intolerant, allergic to fish and their products;
• Current suffering from other organic diseases affecting bowel function, such as history of gastrointestinal resection, colon or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.;
• Diet control, exercise enhancement, or taking medications that control weight or affect appetite in the past 3 months;
• Volunteers have any of the following medical history or have been clinically diagnosed with the following diseases that may affect the evaluation of the test results: obvious gastrointestinal disorders, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases;
• Current or past abuse of alcohol or other illicit drugs, supplements, or OTC prescriptions 3 / 11 Research content Collection of biological samples or information data Evaluation indicators Drugs may cause intestinal dysfunction or affect the evaluation of trial effects;
• Frequent use of drugs that may affect gastrointestinal function or immune system according to the investigator's judgment.

Sponsors & Collaborators

• Amway (China) R&D Center: lead

Study Sites (1)

Shanghai MCC Hospital

Shanghai, Shanghai Municipality, 201900, China

Location

MeSH Terms

Conditions

Metabolic Diseases

Condition Hierarchy (Ancestors)

Nutritional and Metabolic Diseases

Study Officials

• Zheng Qu

  Shanghai MCC Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Charlie Zhang, MD

CONTACT

+8613901981272; charlie.zhang@raisonbiotech.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2025
• First Posted: September 8, 2025
• Study Start: October 9, 2025
• Primary Completion: April 10, 2026
• Study Completion (Estimated): May 10, 2026
• Last Updated: September 12, 2025

Record last verified: 2025-09

Locations

CN (1)